Indivior PLC (INDV) has released its full-year 2026 financial guidance, projecting revenue between $870 million and $910 million and adjusted EBITDA of $410 million to $430 million. The outlook reflects continued momentum in its addiction treatment portfolio and strategic investments in R&D and commercial expansion.
- Revenue guidance for 2026: $870 million to $910 million
- Adjusted EBITDA forecast: $410 million to $430 million
- R&D investment planned at $120 million in 2026
- Expected net debt below $1.1 billion by December 2026
- Adjusted EBITDA margin range: 45% to 47%
- Focus on expanding global access to Suboxone and next-generation treatments
Indivior PLC (INDV) has issued its official financial guidance for the full year 2026, setting a revenue range of $870 million to $910 million and adjusted EBITDA between $410 million and $430 million. The company attributes this forecast to sustained demand for its FDA-approved medications, including Suboxone, and expanded market access in key international regions. The guidance signals a disciplined approach to growth, with management emphasizing reinvestment in research and development initiatives targeting next-generation opioid use disorder treatments. Specifically, the company plans to allocate approximately $120 million toward clinical development and regulatory submissions over the next 12 months, reflecting long-term strategic priorities. Analysts note that the adjusted EBITDA margin guidance of 45% to 47% indicates improved operational efficiency and cost management, despite ongoing investments. This margin range is consistent with the company’s historical performance and suggests confidence in its ability to scale profitability amid competitive pressures in the specialty pharmaceutical space. Market participants are closely monitoring INDV’s guidance as a barometer for sector-wide trends in addiction therapeutics. The release has prompted early interest from institutional investors, with options activity on INDV showing elevated call volume ahead of the next earnings cycle. The guidance also reinforces the company’s commitment to maintaining a strong balance sheet, with net debt expected to remain below $1.1 billion by year-end 2026.